
Brief intro:
- Author: Jinghui Song, Liting Dong, Hanxiao Sun, Nan Luo, Qiang Huang, Kai Li, Xiaowen Shen, Zhe Jiang, Zhicong Lv, Luxin Peng, Meifang Zhang, Kun Wang, Ke Liu, Jiaxu Hong, Chengqi Yi
- Journal: Molecular Cell
- Doi: https://www.doi.org/10.1016/j.molcel.2022.11.011
- Publication Date: 2023 Jan 5
Products/Services used in the paper
Quotation shows PackGene:RESTARTv2 expressing AAVs were packaged in PackGene Company.
Research Field:RNA editing
AAV Serotype:AAV6.2; AAVDJ
Animal or cell line strain:HDF and HBE cells were seeded at density of 3 x 10^5 in T75 flask, B-Lymphocytes were seeded at density of 2 x 10^5/ml, and MEFs were seeded into 100 mm culture dishes at a density of 1.5 x 10^5 cells. 24 hours after seeding, cells were transduced by AAV6.2 (EEF2- U1570/EEF2- 2881/PPIB-U272/CFTR-W1282X) at multiplicities of infection 1 x 10^6 (for HDF), 1 x 10^5 (for HBE), and 1 x 10^5 (for B-Lymphocytes). MEFs were transduced by AAVDJ (Idua-W392X) at multiplicities of infection 5 x 10^6. Cell medium were changed 24 hours after transduction. 7 days after transduction, cells were collected.
Abstract
Nonsense mutations, accounting for >20% of disease-associated mutations, lead to premature translation termination. Replacing uridine with pseudouridine in stop codons suppresses translation termination, which could be harnessed to mediate readthrough of premature termination codons (PTCs). Here, we present RESTART, a programmable RNA base editor, to revert PTC-induced translation termination in mammalian cells. RESTART utilizes an engineered guide snoRNA (gsnoRNA) and the endogenous H/ACA box snoRNP machinery to achieve precise pseudouridylation. We also identified and optimized gsnoRNA scaffolds to increase the editing efficiency. Unexpectedly, we found that a minor isoform of pseudouridine synthase DKC1, lacking a C-terminal nuclear localization signal, greatly improved the PTC-readthrough efficiency. Although RESTART induced restricted off-target pseudouridylation, they did not change the coding information nor the expression level of off-targets. Finally, RESTART enables robust pseudouridylation in primary cells and achieves functional PTC readthrough in disease-relevant contexts. Collectively, RESTART is a promising RNA-editing tool for research and therapeutics.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
